CKChang-Yuil Kang

Chang-Yuil Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chang-Yuil Kang has a total of 209 co-authors. Here are the top co-authors by number of shared publications:

  • Yeonseok Chung

    College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea

    12 shared publications
  • Hyungseok Seo

    Laboratory of Immunology, Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea

    10 shared publications
  • Insu Jeon

    Laboratory of Immunology, Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea

    10 shared publications
  • Boyeong Song

    Research & Development Center, Cellid Co. Ltd. Seoul South Korea

    9 shared publications
  • Byung-Seok Kim

    Division of Life Sciences, College of Life Science and Bioengineering, Incheon National University, Incheon, South Korea

    8 shared publications
  • Hyun-Jeong Ko

    Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon 24341, Korea

    8 shared publications

Latest Publications

  • Evaluation of Simultaneous Production Strategies for Adenoviral Vector-Based SARS-CoV-2 Multivalent Vaccines via an Expanded Allele-specific Competitive Blocker PCR Quantification Method

    by Soojeong Chang, Hyemin Park, Jieun Shin, Seowoo Park, Bongju Park, Chang-Yuil Kang

    As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, developing multivalent vaccines becomes crucial to ensure broader immunogenicity against the emerging variants. Traditional multivalent vaccines are produced by combining separately formulated monovalent vaccines in equal proportions, which necessitates precisely quantifying each component. However, the minimal differences in SARS-CoV-2 spike protein sequences among variants pose challenges for immunological quantification methods. In this study, we established an allele-specific competitive blocker polymerase chain reaction (ACB-PCR)-based quantification method to accurately determine the composition of a multivalent adenoviral vector-based SARS-CoV-2 vaccine. By designing primers tailored to each variant and integrating a blocker for target-specific amplification, we achieved high accuracy in distinguishing closely related spike protein variants. Additionally, we explored coinfection and cotransfection strategies as alternative approaches for the simultaneous production of multivalent vaccines. Our results indicated that both these methods maintained antigen composition within a percentage error of approximately 10%, thereby supporting their feasibility for large-scale vaccine manufacturing. This study provides a robust molecular quantification tool for multivalent vaccine analysis and highlights efficient coproduction strategies that could enhance vaccine manufacturing scalability and responsiveness to emerging SARS-CoV-2 variants.

  • Continuous Tracking for Effective Tackling: Ad5/35 Platform‐Based JN1 Lineage Vaccines Development in Response to Evolving SARS‐CoV‐2 Variants

    by Soojeong Chang, Jieun Shin, Seowoo Park, Hyemin Park, Jong Heon Kim, Tae Wan Kim, In Kyung Jung, Boyeong Song, Kwang‐Soo Shin, Bongju Park, et al.

    The SARS‐CoV‐2 virus is continuously evolving, such that JN.1 and its subvariants, including KP.2, KP.3, and LB.1, are now predominant variants globally. JN.1 is derived from BA.2.86, which harbors more than 30 mutations in the spike protein compared with those of XBB and BA.2, and it carries an additional L455S mutation. Given the rapid evolution of these variants, assessing the neutralization capacity of current JN.1 lineage vaccines against prevalent variants, such as KP.3, is critical. Phylogenetic trees using spike protein sequences and antigenic cartography based on neutralization results reveal that JN.1 lineage variants are antigenically distant from previously circulating variants. Moreover, JN.1 subvariants showed inadequate neutralization titers compared with other variants against XBB.1.5‐containing vaccine in mice. Immunization with vaccines targeting the JN.1, KP.2, KP.3, and LB.1 variants demonstrated significant neutralizing activity against predominant variants in mice. These results highlight the importance of vaccine development to keep pace with the evolution of SARS‐CoV‐2 variants and the need for updated vaccines targeting the JN.1 variant.


  • Open Access

    IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials

    by Choong-Hyun Koh, Byung-Seok Kim, Chang-Yuil Kang, Yeonseok Chung, Hyungseok Seo

    Koh CH, et al. Immune Netw. 2024 Jan;24(1):e2. https://doi.org/10.4110/in.2024.24.e2


  • Open Access

    Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice

    by Kwang-Soo Shin, Byung-Seok Kim, Soojeong Chang, In Kyung Jung, Hyemin Park, Seowoo Park, Jieun Shin, Jong Heon Kim, Sang Jun Han, Bongju Park, et al.


  • Open Access

    The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates

    by Seung-Phil Shin, Kwang-Soo Shin, Jeong-Mi Lee, In-Kyung Jung, Jimo Koo, Seung-Woo Lee, Seowoo Park, Jieun Shin, Myunghwan Park, Bongju Park, et al.

    Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with a single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced Th1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.


  • Open Access

    The Chimeric Adenovirus(Ad5/35) Expressing Engineered Spike Protein Confers Immunity Against SARS-Cov-2 in Mice and Non-Human Primates

    by Seung-Phil Shin, Kwang-Soo Shin, Jeong-Mi Lee, In-Kyung Jung, Jimo Koo, Seung-Woo Lee, Seowoo Park, Jieun Shin, Myunghwan Park, Bongju Park, et al.

    Several COVID-19 platforms have been licensed across the world thus far, but vaccine platforms research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced Th1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.


  • Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells

    by Jeong-Mi Lee, Kwang-Soo Shin, Choong-Hyun Koh, Boyeong Song, Insu Jeon, Myung Hwan Park, Byung-Seok Kim, Yeonseok Chung, Chang-Yuil Kang


  • Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.

    by Chel Hun Choi, Byoung-Gie Kim, Jeong-Won Lee, Duk-Soo Bae, Eun-Suk Kang, Yong-Man Kim, Kidong Kim, Jae-Weon Kim, Young-Tae Kim, Myong Cheol Lim, et al.

    5512 Background: BVAC-C is a B cell- and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, which was well tolerated in HPV positive recurrent cervical carcinoma in phase I study (J Clin Med. 2020 Jan 5;9(1):147). This phase IIa study sought to determine the antitumor activity of BVAC-C. Methods: Twenty-one patients with HPV 16 or 18 positive recurrent cervical cancer who had experienced recurrence after one prior platinum-based combination chemotherapy were enrolled. They were allocated to 3 arms; Arm 1, BVAC-C injection at 0, 4, 8 weeks (1x108 cells/dose); Arm 2, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose); Arm 3, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose) with topotecan at 2, 6, 10, 14 weeks (0.75 mg/m2 for 3 days). Results: The overall response rate was 21% (Arm 1: 29% (2/7), Arm 2: 25% (1/4), Arm 3 : 0 % (0/3)) among the evaluable patients (N = 14), and the median duration of response was 18 months (range, 9 – 26 months). The disease control rate was 43% (Arm 1: 29% (2/7), Arm 2: 50% (2/4), Arm 3 : 67 % (2/3)) and the median duration of stable disease were 12 months (range, 6 - 26 months). The median progression-free survival in all patients was 4 months (95% CI, 2 to Infinite months). Immune responses of patients after vaccination were shown to be correlated with clinical responses of them. Consistent with Phase I study, all evaluated patients showed not only inflammatory cytokine responses (IFN-γ or TNF-α), which might be mediated by the activation of natural killer cells and natural killer T cells, but also potent E6/E7-specific T cell responses upon vaccinations. Conclusions: BVAC-C demonstrated a durable antitumor activity with an immune response in HPV 16- or 18-positive recurrent cervical carcinoma patients who failed 1st line platinum based chemotherapy. Clinical trial information: NCT02866006.


  • Open Access

    Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

    by Insu Jeon, Jeong-Mi Lee, Kwang-Soo Shin, Taeseung Kang, Myung Hwan Park, Hyungseok Seo, Boyeong Song, Choong-Hyun Koh, Jeongwon Choi, Young Kee Shin, et al.

    For cancer vaccines, the selection of optimal tumor-associated antigens (TAAs) that can maximize the immunogenicity of the vaccine without causing unwanted adverse effects is challenging. In this study, we developed two engineered Human epidermal growth factor receptor 2 (HER2) antigens, K965 and K1117, and compared their immunogenicity to a previously reported truncated HER2 antigen, K684, within a B cell and monocyte-based vaccine (BVAC). We found that BVAC-K965 and BVAC-K1117 induced comparable antigen-specific antibody responses and antigen-specific T cell responses to BVAC-K684. Interestingly, BVAC-K1117 induced more potent antitumor activity than the other vaccines in murine CT26-HER2 tumor models. In addition, BVAC-K1117 showed enhanced antitumor effects against truncated p95HER2-expressing CT26 tumors compared to BVAC-K965 and BVAC-K684 based on the survival analysis by inducing T cell responses against intracellular domain (ICD) epitopes. The increased ICD epitope-specific T cell responses induced by BVAC-K1117 compared to BVAC-K965 and BVAC-K684 were recapitulated in human leukocyte antigen (HLA)-untyped human PBMCs and HLA-A*0201 PBMCs. Furthermore, we also observed synergistic antitumor effects between BVAC-K1117 and anti-PD-L1 antibody treatment against CT26-HER2 tumors. Collectively, our findings demonstrate that inclusion of a sufficient number of ICD epitopes of HER2 in cellular vaccines can improve the antitumor activity of the vaccine and provide a way to optimize the efficacy of anticancer cellular vaccines targeting HER2.


  • GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells

    by Choong-Hyun Koh, Il-Kyu Kim, Kwang-Soo Shin, Insu Jeon, Boyeong Song, Jeong-Mi Lee, Eun-Ah Bae, Hyungseok Seo, Tae-Seung Kang, Byung-Seok Kim, et al.

    Although treatment with the glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) agonistic antibody (DTA-1) has shown antitumor activity in various tumor models, the underlying mechanism is not fully understood. Here, we demonstrate that interleukin (IL)-21–producing follicular helper T (Tfh) cells play a crucial role in DTA-1–induced tumor inhibition. The administration of DTA-1 increased IL21 expression by Tfh cells in an antigen-specific manner, and this activation led to enhanced antitumor cytotoxic T lymphocyte (CTL) activity. Mice treated with an antibody that neutralizes the IL21 receptor exhibited decreased antitumor activity when treated with DTA-1. Tumor growth inhibition by DTA-1 was abrogated in Bcl6fl/flCd4Cre mice, which are genetically deficient in Tfh cells. IL4 was required for optimal induction of IL21-expressing Tfh cells by GITR costimulation, and c-Maf mediated this pathway. Thus, our findings identify GITR costimulation as an inducer of IL21-expressing Tfh cells and provide a mechanism for the antitumor activity of GITR agonism.